Assessment of DDR2, BRAF, EGFR and KRAS mutations as therapeutic targets in non-adenocarcinoma lung cancer patients.
about
Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes.Potential Molecular Targets in the Treatment of Lung Cancer Using siRNA Technology.Prevalence of Mutations in Discoidin Domain-Containing Receptor Tyrosine Kinase 2 (DDR2) in Squamous Cell Lung Cancers in Korean Patients.Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients
P2860
Assessment of DDR2, BRAF, EGFR and KRAS mutations as therapeutic targets in non-adenocarcinoma lung cancer patients.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Assessment of DDR2, BRAF, EGFR ...... arcinoma lung cancer patients.
@en
Assessment of DDR2, BRAF, EGFR ...... arcinoma lung cancer patients.
@nl
type
label
Assessment of DDR2, BRAF, EGFR ...... arcinoma lung cancer patients.
@en
Assessment of DDR2, BRAF, EGFR ...... arcinoma lung cancer patients.
@nl
prefLabel
Assessment of DDR2, BRAF, EGFR ...... arcinoma lung cancer patients.
@en
Assessment of DDR2, BRAF, EGFR ...... arcinoma lung cancer patients.
@nl
P2093
P2860
P356
P1476
Assessment of DDR2, BRAF, EGFR ...... arcinoma lung cancer patients.
@en
P2093
Hideaki Yashima
Izumi Takeyoshi
Jun Atsumi
Kimihiro Shimizu
Koujirou Yamamoto
Takuya Araki
Tohru Aomori
Tomonori Nakamura
Toshiteru Nagashima
Yasuaki Enokida
P2860
P304
P356
10.3892/MCO.2014.302
P577
2014-06-03T00:00:00Z